The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...

Kite Pharma's viral vector plant in Southern California has been cleared for liftoff, and, with that, the Gilead Sciences company is touting its position as the only cell therapy player able to make ...

As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Human embryonic kidney (HEK293) cells are the most commonly used cell line to produce viral vectors for gene therapy. Due to the complexity of their production and purification, viral vectors can be ...

VectorBuilder’s manufacturing center in Guangzhou, China, will work with Univercells Technologies to develop and optimize platform processes for the production of custom viral vectors for cell and ...

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing Markets and Technologies Through 2030" report has been added to ResearchAndMarkets.com's offering. The global market for viral ...